Blue callout with text #1 Dispensed Psoriasis Topical by Canadian Dermatologists with maple leaf icon on the right side

*Comparative clinical significance is unknown.

For Healthcare Professionals

Thumbnail image of Enstilar® Clinical Trial Results Brochure

Clinical Trial Results Brochure

Enstilar® (calcipotriol / betamethasone dipropionate) logo

Product Monograph


For Patients

Thumbnail image of Enstilar® Patient Starter Guide

Patient Starter Guide

Thumbnail image of Using Enstilar® Tear Pad

Using Enstilar® Tear Pad


Enstilar® Safety Information

Indication and Clinical Use:
Enstilar® is indicated for the topical treatment of psoriasis vulgaris in adults for up to 4 weeks.

The use in pediatrics (<18 years of age) is not recommended as safety and efficacy have not been established in this population.

● Disorders of calcium metabolism
● Viral skin lesions; fungal, bacterial, parasitic skin infections; skin manifestations related to tuberculosis
● Perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds
● Erythrodermic and pustular psoriasis

Relevant warnings and precautions:
● Long-term or concomitant corticosteroid use
● Use with ultraviolet radiation
● Avoid use on broken skin, on mucous membranes, in skin folds, or under occlusive dressing
● Hypercalcemia and hypercalciuria
● Hepatic or renal impairment
● Avoid ophthalmic use
● Avoid use on face, axillae, flexures, groin, or genitals
● Use caution in pregnant patients
● Avoid use on breast if breastfeeding
● Use in children <18 years of age or the elderly ≥65 years of age

For more information:
Please consult the Product Monograph at for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available by calling LEO Pharma Medical Information at 1-800-263-4218.

© 2020 LEO Pharma Inc. All rights reserved.
® Registered trademark of LEO Pharma A/S used under license
and distributed by LEO Pharma Inc.


  1. IQVIA GPM TRX Audit. April 2020.